Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;36(2):273-277.
doi: 10.1038/s41433-021-01722-8. Epub 2021 Aug 9.

Next-generation anti-VEGF agents for diabetic macular oedema

Matias Iglicki #  1 , David Pérez González #  2 , Anat Loewenstein  2 , Dinah Zur  2
Affiliations
Review

Next-generation anti-VEGF agents for diabetic macular oedema

Matias Iglicki et al. Eye (Lond). 2022 Feb.

Abstract
in English, Chinese

The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.

随着玻璃体腔内注射治疗药物的引入, 糖尿病性黄斑水肿 (DMO) 的治疗和预后得到了改善。然而, 真实数据显示, DMO治疗的负担导致随机临床试验和日常临床实践之间的结果存在巨大差距。DMO长效玻璃体腔内药物和装置可能通过更可行的注射方案实现最佳治疗, 从而减少这种差异。在这篇手稿中, 我们介绍了brolucizumab单抗、faricimab单抗、康柏西普、KSI-301和药物递送系统 WR42221的药效学、临床试验的初步结果及安全评估。这些治疗可能是现实生活中控制糖尿病眼病全球流行的第一步。

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49. doi: 10.1016/j.diabres.2013.11.002. - DOI - PubMed
    1. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–63. doi: 10.1001/archopht.122.4.552. - DOI - PubMed
    1. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64. doi: 10.2337/dc11-1909. - DOI - PMC - PubMed
    1. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: Results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. doi: 10.1016/j.ophtha.2011.12.039. - DOI - PubMed
    1. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25. doi: 10.1016/j.ophtha.2011.01.031. - DOI - PubMed

MeSH terms

Substances